ACP
BHVN icon

Altitude Crest Partners’s Biohaven BHVN Stock Holding History

Altitude Crest Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-118,380
Closed -$6.47M – 7
2024
Q1 		$6.47M Buy
+118,380
New +$5.86M 2.77% 12

Other funds holding BHVN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Altitude Crest Partners's BHVN Position: Q2 2024 in Review

Altitude Crest Partners sold out of Biohaven (BHVN) in Q2 2024, closing a stake of 118,380 shares — an estimated $6.47M sold.

Altitude Crest Partners first reported a position in BHVN in Q1 2024 and held it in 1 quarter. The position peaked at $6.47M in Q1 2024. 225 funds tracked by Wall St. Rank hold BHVN as of Q2 2024.

  • Altitude Crest Partners reported no remaining Biohaven position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 118,380 Biohaven shares in Q2 2024, an estimated $6.47M.
  • Altitude Crest Partners first reported a position in Biohaven in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Biohaven position peaked at $6.47M in Q1 2024.
  • 225 funds tracked by Wall St. Rank held Biohaven as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.